drugset / Trial / NCT01355614

A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients

NCT01355614

Phase 2 Completed 10 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the safety and efficacy of QAX576 if patients with fistulizing Crohn's disease.

Timeline

Start
2011-06
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Infliximab Monoclonal antibody
Subject QAX576 Monoclonal antibody

Indications